Bloomberg: Samsung Biologics And Wuxi Biologics Plan IPOs For their Biologic CMOs
Published: Oct 17, 2016
Two Asian biologic contract manufacturing organizations, Samsung Biologics and WuXi Biologics, have IPOs in the works. Samsung announced a $2 billion Korean IPO in September, while WuXi plans a $500 million Hong Kong initial offering early next year. The Samsung transaction has been officially announced; a Bloomberg article predicted the WuXi IPO, based on a report from an unidentified insider. The two companies are vying to become leaders in biologics, a sector of the greater pharma market that will be just as important as small molecule drugs in less than ten years.